Marrow Therapeutics unveiled an OrbiMed-led $120 million Series B on November 17 to develop blood-disease treatments that patients could receive through repeated injections. The Watertown, Massachusetts, biotech is targeting sickle cell disease and beta thalassemia.
Its lead candidate, MAR-101, is designed for injections under the skin, with doses that could be adjusted or repeated if its effects fade. Casgevy, an existing gene therapy, uses a patient’s stem cells modified in a laboratory and returned after chemotherapy.
MAR-101 pairs an antibody with a small RNA molecule intended to restore production of fetal hemoglobin, which can compensate for defective adult hemoglobin. The antibody carries that cargo into bone marrow cells through TfR1, a receptor involved in iron uptake. The RNA targets BCL11A, a protein that suppresses fetal hemoglobin.
The Series B follows a $53 million Series A co-led by Scion Life Sciences, which founded Marrow, and venBio. Together, the rounds account for the $173 million disclosed at launch. Existing backers joined the Series B alongside investors including RTW Investments and KKR.
CEO Romesh Subramanian told Fierce Biotech that earlier approaches targeting TfR1 had encountered anemia risks, and said Marrow had overcome that problem. MAR-101 remains in preclinical studies needed before applying to begin human testing; its safety and effectiveness in patients have yet to be established.
The financing will also support manufacturing capacity, Subramanian told BioPharma Dive. In the launch announcement, Scion co-founder Aaron Kantoff said he expected Marrow’s programs to advance into clinical testing in the coming year.